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Psoriasis appears in most cases to be a 
genetic diseaseR in which stratified squa-
mous epithelium (epidermis) of skin in 
involved versus normal-appearing unin-
volved areas has the following prototypic 
features: (1) excessive cell proliferation 
and an accelerated cell cycle of the pro-
liferating cells2 '; (2) incomplete epidermal 
specialization (keratinization) for tissue 
function; and (3) marked increase in gly-
cogen content. 7 It has been widely held 
that the relative lack of epidermal spe-
cialization is due to the rapid transit of 
cells through the epidermis (i.e., the cells 
are shed from the patient without sufficient 
time for normal keratinization to occur). 
However, an alternate explanation is that 
the excessive cell proliferation is the result 
of an inability of differentiated basal cells 
to make the commitment of specialization. 
For this reason we have listed incomplete 
specialization as one of the three charac-
teristic findings in psoriasis lesions. 
We developed the concept that increased 
proliferation, decreased specialization, and 
increased glycogen content in psoriasis 
lesions might be associated with diminished 
levels of epidermal cyclic adenosine mono-
phosphate (cAMP).1O This concept was 
derived from earlier observations that 
epinephrine inhibits epidermal mitosis in 
Reprint requests to: Dr. John J. Voorhees, Depaltment 
of Dermatology, University of Michigan School of Medi-
cine, Ann Arbor, Micb. 48104. 
vitro and in viv0 3 and also promotes gly-
cogenolysis in most tissuesY Epinephrine 
elevates the levels of cAMP in the tissue, 
which then initiates glycogenolysis.12 Using 
the four criteria of Sutherland, a series of 
experiments" 15-17 were conducted showing 
that epinephrine inhibited the G2 ~ M 
phase of the epidermal cell cycle via a rise 
in the cellular levels of cAMP. 
The concept that deficient cAMP was 
possibly central to the prototypic features 
of the psoriasis lesion was further supported 
by observations of Pastan and his co-
workers9 on malignant cells in culture. 
Lowered steady-state levels of cAMP could 
be found in rapidly dividing cells exhibit-
ing "malignant" growth characteristics. 
When such cells are grown in the presence 
of exogenous cAMP, differentiation appears 
to be promoted since their morphology 
quite closely resembles that of benign cells 
and there is also a slowing of their growth 
rate. It seemed to us that these findings in 
malignant cells in culture might have 
relevance to psoriasis (i.e., both are charac-
terized by rapid growth and lack of cell 
specialization) . 
Thus arose the hypothesis that cAMP 
was responsible for the coordinate regula-
tion of normal epidermal morphogenesis 
(proliferation-specialization) and glycogen 
content. The corollary of this hypothesis 
was that in the presence of low steady-state 
epidermal levels of cAMP one might expect 
to find the coordinate misregulation of 
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epidermal morphogenesis and glycogen 
metabolism (i.e., the three prototypic fea-
tures of the psoriasis lesion). 
To test this postulate we compared 
cAMP levels in involved versus uninvolved 
epidermis from 50 patients using two dif-
ferent assays and three data bases-deoxy-
ribonucleic acid (DNA), protein, and wet 
weight. 14, 18 Depending on the assay and 
denominator selected, the decrease in 
cAMP levels in involved areas was between 
55% and 17%. All decreases were statisti-
cally significant except the 17% that was 
based on wet weight. In our hands DNA 
is the most reliable denominator,t8 and in 
our view the Gilman assay5 for cAMP is 
superior to the method of Brooker, Thomas, 
and Appleman2 since smaller quantities of 
tissue are required. Using this data base 
and the Gilman assay, a 36% (p < 0.005) 
decrease in cAMP levels was found in in-
volved versus uninvolved areas. IS However, 
due to inherent problems in the biologic 
material, any decrease might best be 
viewed as strongly suggestive rather than 
as conclusive.Is 
Since the cAMP level is probably de-
creased in the involved areas, the cause 
of this decrease has been investigated. 
Contrary to the findings of Wright and 
associates,n we have not been able to 
detect a defect in the biosynthesis of 
cAMpI7 if saturating concentrations of 
substrate and hormone are utilized. Pre-
liminary results also indicate that excessive 
release of cAMP from the involved areas 
into the culture medium in vitroI!! does not 
occur. Lastly, preliminary results have been 
obtained indicating that the catalytic ac-
tivity of cAMP phosphodiesterase may be 
increased in involved areas. 20 Although ad-
ditional experiments are required to estab-
lish this increase with certainty, such an 
abnormality if present could explain the de-
creased cAMP levels. 
Recently, another cyclic nucleotide, 
cyclic guanosine monophosphate (cGMP), 
has been implicated in the control of pro-
liferation. For example, cyclic GMP had 
been found to be strikingly elevated in 
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lymphocytes that have been stimulated to 
proliferate with mitogens. G In collaboration 
with Dr. Nelson Goldberg at the University 
of Minnesota, we measured cGMP levels 
in psoriasis areas with increased prolifera-
tion versus uninvolved areas with normal 
proliferation. Cellular levels of cGMP were 
significantly (p < 0.02) increased by all 
three data bases. IS Since cGMP can stimu-
late the hydrolYSiS of cAMP in vitro,1 the 
elevated levels of cGMP observed in 
psoriasis tissue could also account for the 
decreased lli)vels of cAMP in the lesion. 
If decreased cAMp· is central to the 
morphogenetic abnormality of the psoriasis 
lesion, it should be possible to reverse or 
prevent the lesion by raising the epidermal 
cAMP levels. Because cAMP and its deriva-
tives are relatively impermeable to cell 
membranes, we chose to elevate cAMP by 
the use of a known phosphodiesterase 
inhibitor papaverine. Papaverine has been 
demonstrated to raise intraepidermal cAMP 
160% in our laboratory in epidermal 
slices. 1 :1 In a double-blind study with a 1% 
papaverine cream in which 45 patients 
participated, a statistically significant (p < 
0.05) improvement was found. Io However, 
the clinical potency of this particular for-
mulation of papaverine is apprOXimately 
that of 0.5% to 1% hydrocortisone cream 
and is therefore inferior to certain of the 
fluorinated glucocorticoid creams. None-
theless, the fact that a cAMP elevating 
agent improved psoriasis suggests that this 
type of therapy holds promise. The reasons 
for this view have been discussed else-
where. 20 Additional clinical trials of other 
cAMP elevating agents are in progress with 
others scheduled for the near future. 
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